ClinicalTrials.gg
CompletedNCT05919303Updated Jun 26, 2023

Multidetector Computed Tomography (MDCT) Evaluation of Obstructive Jaundice: A Cross-sectional Study From a Tertiary Hospital of Nepal

An observational study in Obstuctive Jaundice and Radiological Correlation of Obstructive Jaundice, sponsored by Shree Birendra Hospital. Completed at 1 site in Nepal. Per ClinicalTrials.gov, last updated 2023-06-26.

Primary conditionJaundice, ObstructiveRegistry: JaundiceReclassifiedWhy we changed it
Registry
Jaundice — the first condition term the registry derived for this study.
ClinicalTrials.gg
Jaundice, Obstructive
Why
  1. The study's listed conditions name Jaundice, Obstructive, a narrower term within Jaundice.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Shree Birendra Hospital · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
30
Sex
All
01

Study summary

This study was done to evaluate the diagnostic statistics of MDCT and its features in the assessment of obstructive jaundice in reference to surgical or histopathological diagnosis.

Read the detailed description

We did a cross-sectional study among 30 participants of obstructive jaundice at BP Koirala Institute of Health Sciences (BPKIHS), Dharan, Nepal. The sensitivity and the Negative predictive value of MDCT for non-neoplastic cause to detect obstructive jaundice were 100% (95% CI 79.41-100.00) and 100% (95% CI 75.29-100.00), while the specificity and the Positive predictive value for neoplastic cause to detect obstructive jaundice were 100% (95% CI: 79.41-100.00) and 100% (95% CI: 75.29-100.00). Similarly, the accuracy for either non-neoplastic or neoplastic cause was 96.67% (95% CI: 82.78-99.92). The most common cause for obstructive jaundice was choledocholithiasis (33.34%) followed by cholangiocarcinoma (20%), ampullary carcinoma (13.33%) and choledochal cyst (13.33%). The diagnostic accuracy of individual etiology of common causes of obstructive jaundice ranged from 82.78 to 100%. Biliary obstruction was most frequently observed in the periampullary region (83.33%), followed by the proximal common bile duct (6.67%), hilar region (6.67%), and intrahepatic region (3.33%).The MDCT could serve as the initial, cost-effective, easily available, and time-efficient imaging modality for diagnosing various causes of obstructive jaundice. It can differentiate non-neoplastic from neoplastic causes of obstructive jaundice.

02

Conditions studied

  • Obstuctive Jaundice
  • Radiological Correlation of Obstructive Jaundice

Browse trials for

03

In context

Jaundice, Obstructive Reclassified

62 studies on the registry are indexed under Jaundice, Obstructive; 15 are open to participants now.

This study's enrollment of 30 is below the median of 125 across 20 observational studies indexed under Jaundice, Obstructive.

Browse Jaundice, Obstructive studies →

Lead sponsor

This is the only study on the registry with Shree Birendra Hospital as lead sponsor.

Compared within Jaundice, Obstructive, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Jaundice. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

30 All patients exhibiting clinical and biochemical features of obstructive jaundice who were referred for MDCT scan and subsequently received a final diagnosis through histopathology, cytopathology or surgical findings were included as participants in the study

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any patient referred for CT scan with findings suggestive of obstructive jaundice with pertinent Histopathological and post-surgical findings .

Exclusion criteria

Exclusion Criteria:

  • Patients with for contrast-enhanced CT, those with non-obstructive cases of jaundice, and patients experiencing recurrent causing obstructive jaundice.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
30 participants (actual)
Patient registry
No

Groups and cohorts

  • Patient presenting with obstructive jaundice referred for CT evaluation

    Radiation: CT Scan

Interventions

  • RadiationCT Scan

    CT scan study of abdomen

06

What researchers measure

Primary outcomes

  1. Evaluate the diagnostic statistics of MDCT and its features in the assessment of obstructive jaundice in reference to surgical or histopathological diagnosis.

    Time frame: one year

07

Study locations

1 site
  • BP Koirala Institute of Health Sciences
    Dharān Bāzār, Koshi, Nepal
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Oct 2020, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2023
First posted
Jun 26, 2023
StartActual
Oct 8, 2019
Primary completionActual
Oct 7, 2020
CompletionActual
Oct 10, 2020
Last update
Jun 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05919303
Lead sponsor
Shree Birendra Hospital
Collaborators
B.P. Koirala Institute of Health Sciences
Responsible party
Asim Mahat (Doctor, Shree Birendra Hospital) — Principal investigator
First posted
Jun 26, 2023
Start date
Oct 8, 2019
Primary completion
Oct 7, 2020
Completion
Oct 10, 2020
Last update
Jun 26, 2023

Study contacts

Asim Mahat, MD
principal investigator · Nepalese Army Institute of Health Sciences

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion